Compare LSPD & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSPD | MPLT |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Canada | United States |
| Employees | N/A | 133 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2020 | N/A |
| Metric | LSPD | MPLT |
|---|---|---|
| Price | $9.91 | $36.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $13.33 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 797.2K | 563.2K |
| Earning Date | 05-21-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.43 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.83 | $12.24 |
| 52 Week High | $14.34 | $40.43 |
| Indicator | LSPD | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 54.74 |
| Support Level | $9.87 | $26.20 |
| Resistance Level | $12.70 | $40.43 |
| Average True Range (ATR) | 0.34 | 2.75 |
| MACD | -0.10 | -0.46 |
| Stochastic Oscillator | 32.74 | 35.78 |
Lightspeed Commerce Inc is a one-stop commerce platform providing its customers with the critical functionalities needed to engage with consumers, manage their operations, order their inventory, accept payments, and run their business. It has customers globally in over 100 countries, empowering single- and multi-location small and medium-sized businesses to compete in an omni-channel market environment by engaging with consumers across online, mobile, social, and physical channels. Its products are divided into retail, restaurant, and golf categories. Geographically, it operates in Canada, the United States, the United Kingdom, Switzerland, Germany, and Others with the majority of revenue deriving from Canada.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.